Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis

Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Yasuyuki Mizutani, Eri Ishikawa, Ayako Ohashi, Go Kajikawa, Kazuhiro Furukawa, Eizaburo Ohno, Takashi Honda, Hiroki Kawashima, Masatoshi Ishigami, Mitsuhiro Fujishiro

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20- year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.

Original languageEnglish
Pages (from-to)3009-3014
Number of pages6
JournalInternal Medicine
Volume59
Issue number23
DOIs
Publication statusPublished - 01-12-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis'. Together they form a unique fingerprint.

Cite this